These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34312925)

  • 1. Chaperonin-containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients.
    Hu Y; Fu P; Zhao H; Zhang F; Jiang X; Zhao W; Lv P
    J Clin Lab Anal; 2021 Sep; 35(9):e23917. PubMed ID: 34312925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCT6A may act as a potential biomarker reflecting tumor size, lymphatic metastasis, FIGO stage, and prognosis in cervical cancer patients.
    Ma J; Yang L; Feng H; Zheng L; Meng H; Li X
    J Clin Lab Anal; 2021 Aug; 35(8):e23793. PubMed ID: 34196992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chaperonin-containing tailless complex polypeptide 1 subunit 6A links with aggravating tumor features and disease-free survival in surgical gastric cancer patients: A long-term follow-up study.
    He T; Yu D; Wang Z; Guo C; Chang Y; Wang D
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101913. PubMed ID: 35346891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCT6A expression in hepatocellular carcinoma and its correlation with clinical characteristics, liver function indexes, tumor markers and prognosis.
    Cai Y; Wu D; Zhan L
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101796. PubMed ID: 34500119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chaperonin containing t-complex polypeptide 1 subunit 6A correlates with lymph node metastasis, abnormal carcinoembryonic antigen and poor survival profiles in non-small cell lung carcinoma.
    Zhang T; Shi W; Tian K; Kong Y
    World J Surg Oncol; 2020 Jul; 18(1):156. PubMed ID: 32631353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCT6A dysregulation in surgical prostate cancer patients: association with disease features, treatment information, and prognosis.
    Peng S; Yu J; Wang Y
    Ir J Med Sci; 2024 Feb; 193(1):85-93. PubMed ID: 37523068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCT6A is associated with CDC20, Enneking stage and prognosis in osteosarcoma, and its knockdown suppresses osteosarcoma cell viability and invasion.
    Wang N; Chen Y; Wu J
    Oncol Lett; 2023 May; 25(5):201. PubMed ID: 37113398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship among integrin alpha 7, CD133 and Nestin as well as their correlation with clinicopathological features and prognosis in astrocytoma patients.
    Li C; Liu J; Yang W; Chen C; Wu B
    Clin Neurol Neurosurg; 2022 Jun; 217():107198. PubMed ID: 35430343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake of
    Yamamura T; Tamura K; Kobayashi D; Inaji M; Toyama Y; Wakimoto H; Kiyokawa J; Hara S; Tanaka Y; Nariai T; Shimizu K; Ishii K; Maehara T
    J Neurooncol; 2024 Jun; 168(2):355-365. PubMed ID: 38557927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCT6A, a novel prognostic biomarker for Ewing sarcoma.
    Jiang J; Liu C; Xu G; Liang T; Yu C; Liao S; Zhang Z; Lu Z; Wang Z; Chen J; Chen T; Li H; Zhan X
    Medicine (Baltimore); 2021 Jan; 100(4):e24484. PubMed ID: 33530265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
    Zhang M; Pan Y; Qi X; Liu Y; Dong R; Zheng D; Chang Q; Zhang J; Fang W; Zhong Y
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):101-107. PubMed ID: 27258564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.
    Galbraith K; Garcia M; Wei S; Chen A; Schroff C; Serrano J; Pacione D; Placantonakis DG; William CM; Faustin A; Zagzag D; Barbaro M; Eibl MDPGP; Shirahata M; Reuss D; Tran QT; Alom Z; von Deimling A; Orr BA; Sulman EP; Golfinos JG; Orringer DA; Jain R; Lieberman E; Feng Y; Snuderl M
    Neuro Oncol; 2024 Jun; 26(6):1042-1051. PubMed ID: 38243818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular Vesicles from Neurosurgical Aspirates Identifies Chaperonin Containing TCP1 Subunit 6A as a Potential Glioblastoma Biomarker with Prognostic Significance.
    Hallal S; Russell BP; Wei H; Lee MYT; Toon CW; Sy J; Shivalingam B; Buckland ME; Kaufman KL
    Proteomics; 2019 Jan; 19(1-2):e1800157. PubMed ID: 30451371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas.
    Cimino PJ; Holland EC
    Neuro Oncol; 2019 Jun; 21(6):819-821. PubMed ID: 30918961
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression.
    Grau SJ; Hampl JA; Kohl AC; Timmer M; Duval IV; Blau T; Ruge MI; Goldbrunner RH
    World Neurosurg; 2017 Jul; 103():180-185. PubMed ID: 28377251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
    Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
    Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCT6A and CHCHD2 Are Coamplified with EGFR and Associated with the Unfavorable Clinical Outcomes of Lung Adenocarcinoma.
    Wang H; Wang X; Xu L; Lin Y; Zhang J
    Dis Markers; 2022; 2022():1560199. PubMed ID: 35937942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas.
    Juratli TA; Kirsch M; Robel K; Soucek S; Geiger K; von Kummer R; Schackert G; Krex D
    J Neurooncol; 2012 Jul; 108(3):403-10. PubMed ID: 22410704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [IDH1 mutation and MGMT expression in astrocytoma and the relationship with prognosis after radiotherapy].
    Jiang M; Dong X; Li J; Li J; Qi J
    Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):668-72. PubMed ID: 25567592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.